证券代码：600718 证券简称：东软集团 公告编号：临 2025-033 关于 2024 年股票期权激励计划 第一个行权期自主行权实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 东软集团股份有限公司 重要内容提示： ? 2024 年股票期权激励计划（以下简称"本激励计划"）第一个行权期可 行权数量：1,120.136 万份； ? 行权股票来源：公司向激励对象定向发行的本公司 A 股普通股股票； ? 行权起始日：2025 年 5 月 26 日。 于 2025 年 4 月 25 日召开的东软集团股份有限公司（以下简称"公司"）十 届二十次董事会审议通过了《关于公司 2024 年股票期权激励计划第一个行权期 行权条件成就的议案》。根据《东软集团股份有限公司 2024 年股票期权激励计划》 （一）本激励计划已履行的决策程序和信息披露情况 于 2024 年 2 月 26 日召开的公司十届八次董事会审议通过了《关于 <东软集> 团股份有限公司 2024 年股票期权激励计划（草案）>及其摘要的议案》《关于< 东软集团股份有限公 ...

证券代码：600718 证券简称：东软集团 公告编号：临 2025-033 东软集团股份有限公司 关于 2024 年股票期权激励计划 第一个行权期自主行权实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 于 2024 年 2 月 26 日召开的公司十届八次董事会审议通过了《关于<东软集 团股份有限公司 2024 年股票期权激励计划（草案）>及其摘要的议案》《关于< 东软集团股份有限公司 2024 年股票期权激励计划考核管理办法>的议案》以及 《关于提请公司股东大会授权董事会办理 2024 年股票期权激励计划相关事宜的 议案》。具体内容，详见本公司于 2024 年 2 月 28 日刊登在《中国证券报》《上海 证券报》上的相关公告。 于 2024 年 2 月 26 日召开的公司十届四次监事会审议通过了《关于<东软集 团股份有限公司 2024 年股票期权激励计划（草案）>及其摘要的议案》《关于< 东软集团股份有限公司 2024 年股票期权激励计划考核管理办法>的议案》。具体 内容，详见本公司于 2024 年 2 月 28 ...

北京市海问律师事务所 关于东软集团股份有限公司 2024 年股票期权激励计划调整股票期权行权价格、注销部分已授予 但尚未行权的股票期权、第一个行权期行权条件成就的 法律意见书 致：东软集团股份有限公司 北京市海问律师事务所（以下简称"本所"）是具有中华人民共和国（以下 简称"中国"）法律执业资格的律师事务所。本所接受东软集团股份有限公司（以 下简称"公司"或"东软集团"）的委托，担任东软集团实施 2024 年股票期权激 励计划（以下简称"本次股权激励计划"）的专项法律顾问，就公司本次股权激 励计划调整股票期权行权价格（以下简称"本次调整"）、注销部分已授予但尚未 行权的股票期权（以下简称"本次注销"）、第一个行权期激励对象行权（以下简 称"本次行权"）相关事宜，出具本法律意见书。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简 称"《管理办法》"）等法律、法规和规范性文件以及《东软集团股份有限公司章 程》（以下简称"《公司章程》"）的规定，对东软集团提供的有关文件和本次调整、 本次注销、本次行权的有关事实进 ...

证券代码：600718 证券简称：东软集团 公告编号：临 2025-034 东软集团股份有限公司 关于发行股份购买资产并募集配套资金 事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担相应的法律责任。 一、本次交易概况 东软集团股份有限公司（以下简称"公司"或"东软集团"）正在筹划通过 发行股份的方式购买上海思芮信息科技有限公司 43.00%股权并募集配套资金 （以下简称"本次交易"）。本次交易不构成《上市公司重大资产重组管理办法》 规定的重大资产重组，构成关联交易，不构成重组上市。 于 2025 年 3 月 10 日召开的公司十届十八次董事会审议通过了《关于现金收 购上海思芮信息科技有限公司 57%股权的议案》《关于公司签署附条件生效的支 付现金购买资产协议之补充协议的议案》等议案。具体内容，详见本公司于 2025 年 3 月 11 日刊登在《中国证券报》《上海证券报》上的相关公告。目前，公司已 与现金收购相关方分别签署附条件生效的《支付现金购买资产协议之补充协议》。 上述议案，待提交公司股东大会审议批准。 于 2025 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [3][10] Core Insights - The company has achieved revenue growth of 9.64% year-on-year, reaching 11.56 billion yuan, and has set a record high in operating cash flow at 855 million yuan [2] - The company is accelerating its global expansion in the smart automotive sector, with a significant increase in orders and shipments, achieving over 30% growth in overall shipments [2] - The company is focusing on "AI + industry" strategies, with notable breakthroughs in "AI + healthcare" and "AI + automotive" sectors, signing new contracts worth 678 million yuan in vertical AI applications [3] Summary by Sections Financial Performance - In 2024, the company achieved a net profit of 435 million yuan, a year-on-year increase of 22.01%, meeting strategic goals [2] - The company’s revenue for the smart automotive interconnection business was 4.70% higher year-on-year, totaling 4.10 billion yuan [8] - The healthcare and social security business revenue decreased by 12.08% to 2.26 billion yuan, but future growth is anticipated [8] Business Segments - The smart city business saw a revenue increase of 49.95%, reaching 2.43 billion yuan, driven by the integration of AI and big data technologies [8] - The enterprise interconnection and other businesses generated 2.77 billion yuan in revenue, up 13.64%, benefiting from the integration of AI models and global service capabilities [8] Future Outlook - The company projects revenues of 12.85 billion yuan, 14.54 billion yuan, and 16.57 billion yuan for 2025, 2026, and 2027 respectively, with net profits expected to rise significantly [10] - The company aims to deepen the integration of AI with industry scenarios and expand application areas, transitioning from a "technology provider" to a "value creator" [9]

Investment Rating - The report maintains a "Buy" rating for Neusoft Corp with a target price of RMB 16.17 [2][6]. Core Insights - Neusoft Corp is expected to benefit from AI-driven opportunities, with all four core business segments anticipated to accelerate growth as downstream customer demand recovers [2][3]. - The company has established a strong competitive advantage in the "AI + healthcare" sector, with significant contracts signed in this area [3][4]. - The operating cash flow reached a historical high of RMB 855 million in 2024, reflecting improved cost management and operational efficiency [4][6]. Financial Performance - In 2024, Neusoft's revenue was RMB 11.56 billion, with a net profit attributable to the parent company of RMB 1.156 billion, showing a year-on-year growth of 9.64% [2][6]. - The company's gross margin for 2024 was 24.01%, a slight decrease of 0.19 percentage points from the previous year, primarily due to a decline in the gross margin of the intelligent connected vehicle segment [4][6]. - For the first quarter of 2025, revenue was RMB 1.85 billion, a year-on-year increase of 1.06%, while the net profit attributable to the parent company was a loss of RMB 12 million [5][6]. Revenue and Profit Forecast - Revenue forecasts for 2025, 2026, and 2027 are projected at RMB 13.3 billion, RMB 15.9 billion, and RMB 19.6 billion, respectively [6][12]. - The net profit attributable to the parent company is expected to be RMB 434 million, RMB 525 million, and RMB 716 million for the years 2025, 2026, and 2027, respectively [6][12]. Market Position and Valuation - The report indicates that Neusoft's valuation is aligned with industry averages, with a projected P/E ratio of 42.4 for 2025 [6][14]. - The potential upside from the current closing price of RMB 9.93 to the target price of RMB 16.17 represents a 63% increase [8].

Core Viewpoint - Neusoft Corporation is actively implementing strategic transformations focusing on AI and data value, leading to significant improvements in operational performance and market position across various sectors, particularly in healthcare and smart automotive solutions [2][3][11]. Group 1: Strategic Transformation and Performance - The company has made substantial progress in its strategic transformation, emphasizing the intelligentization of solutions and data value realization, resulting in a notable increase in net profit and cash flow [3][4]. - In 2024, the company signed new contracts worth 678 million yuan in vertical AI applications and 233 million yuan in data value-related businesses, marking a year-on-year growth of 207% [3][4]. - The company achieved a net profit of 36.13 million yuan, an increase of 111.14 million yuan year-on-year, with a main business net profit growth of 22.01% [3][4]. Group 2: Healthcare Sector Developments - Neusoft maintains the leading market share in healthcare IT solutions, focusing on high-quality reforms in public hospitals and the value realization of healthcare data [4][11]. - The company signed over 30 major healthcare project orders in 2024, enhancing its service capabilities in the healthcare sector [4][11]. - Neusoft's AI-driven healthcare solutions have been implemented in over 90 hospitals, showcasing its commitment to integrating AI with healthcare services [6][11]. Group 3: Smart Automotive Solutions - The company has developed the 8295 smart cockpit platform, achieving significant technological innovations and partnerships with major automotive manufacturers [5][22]. - In 2024, the overall shipment volume of automotive products increased by over 30%, with export-related business growing by 65% [5][24]. - Neusoft's automotive solutions have been recognized with multiple awards, including the "Best Overseas Practice Award" and "Top 10 AI Technology Partners for Chinese Automotive Enterprises" [5][24]. Group 4: Data Value and AI Integration - Neusoft is actively collaborating with various cities to build data value ecosystems, focusing on healthcare, smart cities, and government big data [8][15]. - The company has launched innovative applications in data governance and AI-driven solutions, enhancing its capabilities in the healthcare and social security sectors [15][16]. - Neusoft's cloud-native data platform has strengthened its compatibility with domestic innovations, facilitating the development of data-driven products across multiple industries [8][15]. Group 5: Recognition and Awards - The company has received numerous accolades for its contributions to the software industry and its innovative solutions in AI and healthcare [8][10]. - Neusoft was recognized as a leading enterprise in the new generation of information technology and awarded for its digital government solutions [10][28]. - The company continues to enhance its brand reputation and influence within the digital economy, receiving awards for its smart elderly care services and digital government products [9][10].

| 2024 | 年年度股东大会议程 | | 1 | | --- | --- | --- | --- | | 2024 | 年度董事会报告、2024 | 年年度报告 | 2 | | 2024 | 年度监事会报告 | | 15 | | 2024 | 年度财务决算报告 | | 18 | | 关于 2024 | | 年度利润分配的议案 | 21 | | 关于聘请 | 2025 | 年度审计机构的议案 | 22 | | 关于 2024 | | 年度董事薪酬的议案 | 23 | | 独立董事 | 2024 | 年度述职报告 | 24 | | | | 关于注销公司已回购股份的议案 | 36 | | | | 关于修改公司章程的议案 | 38 | | 关于更换董事的议案 | | | 39 | | 关于 2025 | | 年度日常关联交易预计情况的议案 | 40 | 东软集团股份有限公司 2024 年年度股东大会议程 东软集团股份有限公司 2024 年年度股东大会议程 时间：2025 年 5 月 23 日 下午 13:00 地点：沈阳市浑南新区新秀街 2 号 东软软件园 会议中心 参加人员：股东及股东授权代表、董事会成员、监事 ...

Core Viewpoint - Dongsoft Group is focusing on the intelligentization strategy for solutions in 2024, emphasizing AI and big data to enhance business innovation and achieve significant growth in new contracts [1][2]. Group 1: Business Performance - In 2024, Dongsoft signed new AI application contracts worth 678 million yuan and data value-related contracts worth 233 million yuan, representing a year-on-year growth of 207% [1]. - In Q1 2025, the company signed new AI application contracts worth 189 million yuan and data value-related contracts worth 78 million yuan, with a year-on-year growth of 54% [2]. - The AI+medical business saw a contract amount of 139 million yuan in Q1 2025, marking a year-on-year increase of 211% [2]. Group 2: Product Development - Dongsoft has launched innovative products in the fields of "AI+imaging and auxiliary diagnosis," "AI+medical assistant," and "AI+medical insurance," which are being applied in major medical institutions [3]. - The company released the "AI+medical" full series solution "Tianyi," covering eight medical industry empowerment bodies and implemented in dozens of hospitals [2][3]. - The "Flying Standard Medical Imaging Annotation Platform 5.0" has annotated 55 million images by the end of 2024, recognized as the only recommended commercial tool for AI-assisted marking by clinical experts [3]. Group 3: Strategic Acquisitions - Dongsoft's acquisition of 57% of Sire Technology has been approved by the shareholders' meeting and has passed the review by the State Administration for Market Regulation [4]. - The company is currently advancing the delivery and business change procedures related to this cash acquisition and is negotiating the purchase of the remaining 43% stake [4].

Group 1 - The DRG/DIP concept declined by 3.30%, ranking among the top declines in the concept sector, with notable declines in companies such as Chuangying Huikang, ST Yilianzhong, and Jiahe Meikang [1][2] - The DRG/DIP concept experienced a net outflow of 4.92 billion yuan in main funds, with 19 stocks seeing net outflows, and 13 stocks with outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Donghua Software, with a net outflow of 1.26 billion yuan, followed by Chuangying Huikang, Weining Health, and Dian Diagnosis [2][3] Group 2 - The top stocks with net outflows in the DRG/DIP concept included Donghua Software (-3.97%), Chuangying Huikang (-6.76%), and Weining Health (-4.60%) [2][3] - Conversely, the stocks with net inflows included Huaping Co., Guoke Hengtai, and Wanda Information, with net inflows of 238.84 million yuan, 166.15 million yuan, and 121.00 million yuan respectively [2]